Study Confirms Benefits of Lecanemab in Early Alzheimer Disease
Lecanemab is a humanized monoclonal antibody that works by selectively binding to, neutralizing and eliminating soluble toxic amyloid beta aggregates.
Lecanemab is a humanized monoclonal antibody that works by selectively binding to, neutralizing and eliminating soluble toxic amyloid beta aggregates.
The COSMOS-Mind study included 2262 participants and evaluated the effects of cocoa extract and multivitamin-mineral supplementation on cognitive function.
Researchers sought to evaluate the efficacy of noradrenergic drugs in the improvement of neuropsychiatric and cognitive symptoms in individuals with AD.
Ines Moreno-Gonzalez, PhD, an adjunct associate professor of neurology, explains healthy aging can help reduce lifestyle risk factors for Alzheimer disease.
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
Researchers sought to assess the risk factors for dementia in older adults with atrial fibrillation.
In a large, prospective cohort study, researchers assessed the association between daily total physical activity and the risk of developing disabling dementia in the general Japanese population.
Researchers sought to determine whether concussions and a history of playing football influenced a possible association between ACEs and poor neuropsychiatric health.
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.